Secondary osteoporosis in patients with an osteoporotic fracture
- PMID: 19945688
- DOI: 10.1016/j.berh.2009.09.006
Secondary osteoporosis in patients with an osteoporotic fracture
Abstract
Secondary osteoporosis is a common cause of osteoporosis, and there are many medical conditions associated with osteoporosis. Many of these present well before osteoporosis develops, and knowledge of these pre-existing conditions may influence the decision about whether to test and/or treat for osteoporosis. Men and premenopausal women with unexplained osteoporosis or a history of fragility fracture should undergo investigation for secondary osteoporosis. Postmenopausal women with risk factors for secondary osteoporosis should also be carefully evaluated. Beyond the well-recognised association with glucocorticoids, an increasing list of drugs has been implicated in causing bone loss and fractures. With appropriate consideration of secondary causes and relevant investigations, many of these conditions are preventable with newer therapies.
Similar articles
-
The management of secondary osteoporosis.Best Pract Res Clin Rheumatol. 2005 Dec;19(6):1021-37. doi: 10.1016/j.berh.2005.06.005. Best Pract Res Clin Rheumatol. 2005. PMID: 16301195 Review.
-
Osteoporosis risk in premenopausal women.Pharmacotherapy. 2009 Mar;29(3):305-17. doi: 10.1592/phco.29.3.305. Pharmacotherapy. 2009. PMID: 19249949 Review.
-
Osteoporosis and osteoporotic fractures in men: a clinical perspective.Baillieres Best Pract Res Clin Endocrinol Metab. 2000 Jun;14(2):299-315. doi: 10.1053/beem.2000.0075. Baillieres Best Pract Res Clin Endocrinol Metab. 2000. PMID: 11035908 Review.
-
Epidemiology, etiology, and diagnosis of osteoporosis.Am J Obstet Gynecol. 2006 Feb;194(2 Suppl):S3-11. doi: 10.1016/j.ajog.2005.08.047. Am J Obstet Gynecol. 2006. PMID: 16448873 Review.
-
Glucocorticoid-induced osteoporosis.Curr Opin Endocrinol Diabetes Obes. 2007 Dec;14(6):446-50. doi: 10.1097/MED.0b013e3282f15407. Curr Opin Endocrinol Diabetes Obes. 2007. PMID: 17982350 Review.
Cited by
-
Bone Health in Adults With Prader-Willi Syndrome: Clinical Recommendations Based on a Multicenter Cohort Study.J Clin Endocrinol Metab. 2022 Dec 17;108(1):59-84. doi: 10.1210/clinem/dgac556. J Clin Endocrinol Metab. 2022. PMID: 36149817 Free PMC article.
-
Antiresorptive therapies for osteoporosis: a clinical overview.Nat Rev Endocrinol. 2011 Sep 6;8(2):81-91. doi: 10.1038/nrendo.2011.146. Nat Rev Endocrinol. 2011. PMID: 21894214 Review.
-
Prevalence of less severe hypercortisolism in fractured patients admitted in an outpatient clinic for metabolic bone diseases.Endocrine. 2021 Jul;73(1):203-208. doi: 10.1007/s12020-021-02616-1. Epub 2021 Jan 23. Endocrine. 2021. PMID: 33484412
-
Denosumab in the Management of Glucocorticoid-Induced Osteoporosis: Long-Term Efficacy and Secondary Fracture Outcomes.J Clin Med. 2025 Feb 27;14(5):1633. doi: 10.3390/jcm14051633. J Clin Med. 2025. PMID: 40095574 Free PMC article.
-
When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis.Front Endocrinol (Lausanne). 2021 Dec 15;12:782118. doi: 10.3389/fendo.2021.782118. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34975756 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical